Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | EBP | Q15125 | 1/20 | 0.30 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13697387 | 1.00 | KDM4E (0.33) | KDM4EPOLBALDH1A1HRH3CARM1 | |
| SCHEMBL13697391 | 1.00 | KDM4E (0.33) | KDM4EPOLBALDH1A1HRH3CARM1 | |
| SCHEMBL13697384 | 1.00 | KDM4E (0.33) | KDM4EPOLBALDH1A1HRH3CARM1 | |
| SCHEMBL14494810 | 0.86 | IRAK4 (0.30) | — | |
| SCHEMBL13697365 | 0.86 | IRAK4 (0.30) | — | |
| SCHEMBL13697375 | 0.86 | OPRM1 (0.35) | — | |
| SCHEMBL13697374 | 0.86 | OPRM1 (0.35) | — | |
| SCHEMBL13697376 | 0.86 | OPRM1 (0.35) | — | |
| SCHEMBL13697377 | 0.86 | OPRM1 (0.35) | — | |
| SCHEMBL13697378 | 0.84 | OPRM1 (0.35) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | KDM4E 3759/4885POLB 4406/4885ALDH1A1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.